A role for antiangiogenic therapy in breast cancer

被引：16

作者：

Moses M.A. ^{[1
]}

Harper J. ^{[1
]}

Fernández C.A. ^{[1
]}

机构：

[1] Vascular Biology Program, Children's Hospital, Boston, MA 02115

来源：

Current Oncology Reports | 2004年 / 6卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Breast Cancer; Vascular Endothelial Growth Factor; Tamoxifen; Bevacizumab; Trastuzumab;

D O I：

10.1007/s11912-996-0008-6

中图分类号：

学科分类号：

摘要：

The success of the angiogenesis inhibitor bevacizumab, the vascular endothelial growth factor antagonist that was recently shown to significantly improve the survival of patients with metastatic colon cancer when administered in combination with conventional chemotherapy, has provided proof of principle in clinical trials that antiangiogenesis can be an important strategy in the treatment of cancer. This report reviews the contemporary therapeutic approaches for breast cancer, the essential role that angiogenesis plays in the initiation and progression of this disease, and the strategies that should be considered to make antiangiogenic therapy a successful component of breast cancer treatment. Copyright © 2004 by Current Science Inc.

引用

页码：42 / 48

页数：6

共 61 条

[1]

Folkman J., Angiogenesis and breast cancer, J. Clin. Oncol., 12, pp. 441-443, (1994)

[2]

Folkman J., The influence of angiogenesis research on management of patients with breast cancer, Breast Cancer Res. Treat., 36, pp. 109-118, (1995)

[3]

Folkman J., Angiogenesis in breast cancer, The Breast, pp. 586-603, (1998)

[4]

Rayson D., Vantyghem S.A., Chambers A.F., Angiogenesis as a target for breast cancer therapy, J. Mammary Gland Biol. Neoplasia, 4, pp. 415-423, (1999)

[5]

Wu I., Moses M.A., Angiogenic molecules and mechanisms in breast cancer, Curr. Oncol. Rep., 2, pp. 566-571, (2000)

[6]

Fisher B., Dignam J., Wolmark N., Et al., Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17, J. Clin. Oncol., 16, pp. 441-452, (1998)

[7]

Julien J.P., Bijker N., Fentiman I.S., Et al., Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomized phase III trial 10853, Lancet, 355, pp. 528-533, (2000)

[8]

Lingos T.I., Recht A., Vicini F., Et al., Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 21, pp. 355-360, (1991)

[9]

Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials, Lancet, 355, pp. 1757-1770, (2000)

[10]

Fisher B., Anderson S., Tan-Chiu E., Et al., Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23, J. Clin. Oncol., 19, pp. 931-942, (2001)

← 1 2 3 4 5 6 7 →